MX2024001877A - Tratamiento de dermatitis atopica. - Google Patents

Tratamiento de dermatitis atopica.

Info

Publication number
MX2024001877A
MX2024001877A MX2024001877A MX2024001877A MX2024001877A MX 2024001877 A MX2024001877 A MX 2024001877A MX 2024001877 A MX2024001877 A MX 2024001877A MX 2024001877 A MX2024001877 A MX 2024001877A MX 2024001877 A MX2024001877 A MX 2024001877A
Authority
MX
Mexico
Prior art keywords
antigen
atopic dermatitis
antibody
ox40l
methods
Prior art date
Application number
MX2024001877A
Other languages
English (en)
Spanish (es)
Inventor
Ben Porter-Brown
Sonia Quaratino
A Sainson Richard C
John Powell
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2115152.7A external-priority patent/GB202115152D0/en
Priority claimed from GBGB2204211.3A external-priority patent/GB202204211D0/en
Priority claimed from GBGB2204291.5A external-priority patent/GB202204291D0/en
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of MX2024001877A publication Critical patent/MX2024001877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024001877A 2021-08-10 2022-08-09 Tratamiento de dermatitis atopica. MX2024001877A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB202111492 2021-08-10
GBGB2115152.7A GB202115152D0 (en) 2021-10-21 2021-10-21 Treatment of atopic dermatitis
GBGB2204211.3A GB202204211D0 (en) 2022-03-24 2022-03-24 Treatment of atopic dermatitis
GBGB2204291.5A GB202204291D0 (en) 2022-03-25 2022-03-25 Treatment of atopic dermatitis
PCT/GB2022/052070 WO2023017252A1 (en) 2021-08-10 2022-08-09 Treatment of atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2024001877A true MX2024001877A (es) 2024-02-28

Family

ID=82942548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001877A MX2024001877A (es) 2021-08-10 2022-08-09 Tratamiento de dermatitis atopica.

Country Status (11)

Country Link
US (2) US20230235069A1 (https=)
EP (1) EP4384270A1 (https=)
JP (1) JP2024530954A (https=)
KR (1) KR20240043789A (https=)
AR (1) AR126749A1 (https=)
AU (1) AU2022326849A1 (https=)
CA (1) CA3228708A1 (https=)
IL (1) IL310701A (https=)
MX (1) MX2024001877A (https=)
TW (1) TW202330023A (https=)
WO (1) WO2023017252A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024261177A1 (en) * 2023-06-20 2024-12-26 Kymab Limited Dosing and treatment of immune-mediated diseases and biomarkers associated with immune-mediated diseases
WO2025090570A1 (en) * 2023-10-23 2025-05-01 Abcellera Biologics Inc. Anti-ox40l antibodies and methods of use
WO2025233445A1 (en) * 2024-05-08 2025-11-13 Kymab Limited Treatment of head and neck atopic dermatitis
WO2025255353A1 (en) * 2024-06-06 2025-12-11 Apogee Therapeutics, Inc. Dosage and administration of an anti-ox40l antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP3309176B1 (en) * 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
GB201403775D0 (en) * 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015301338C1 (en) * 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
US9512229B2 (en) * 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Also Published As

Publication number Publication date
US20230235069A1 (en) 2023-07-27
KR20240043789A (ko) 2024-04-03
JP2024530954A (ja) 2024-08-27
WO2023017252A1 (en) 2023-02-16
EP4384270A1 (en) 2024-06-19
TW202330023A (zh) 2023-08-01
IL310701A (en) 2024-04-01
AU2022326849A1 (en) 2024-03-21
CA3228708A1 (en) 2023-02-16
US20250353918A1 (en) 2025-11-20
AR126749A1 (es) 2023-11-08

Similar Documents

Publication Publication Date Title
MX2024001877A (es) Tratamiento de dermatitis atopica.
IL299376A (en) Fixed dose combination of pertuzumab plus transtuzumab
Nguyen et al. Evidence and recommendations for use of intra-articular injections for knee osteoarthritis
FI3515937T3 (fi) Refraktaarisen migreenin hoito
AR082390A1 (es) Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX379982B (es) Formulación para usarse en el tratamiento del síndrome de hunter.
JP2019521156A5 (https=)
RU2012108108A (ru) Концентрированные полипептидные лекарственные формы с пониженной вязкостью
Sherif et al. Dexamethasone as adjuvant for femoral nerve block following knee arthroplasty: a randomized, controlled study
Batifol et al. Effect of intra-articular Botulinum toxin injections on temporo-mandibular joint pain
Sigurgeirsson et al. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial
Warnatz et al. Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies
Kim et al. A comparison of the effectiveness of complex decongestive physiotherapy and stellate ganglion block with triamcinolone administration in breast cancer-related lymphedema patients
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
Kayacan Efficacy of neural prolotherapy versus local corticosteroid soft tissue injection for treatment of chronic anserine bursitis: a prospective randomized clinical trial
RU2463045C1 (ru) Способ лечения цереброваскулярных заболеваний и астенического синдрома
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa
WO2023056355A3 (en) Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
Jagatsinh et al. Audit of safety of intramuscular botulinum toxin injections among patients receiving warfarin anticoagulation therapy
EA202092978A3 (ru) Фармацевтическая композиция для парентерального капельного введения
RU2762499C2 (ru) Внутрикожное введение препарата иммуноглобулина G
MX2025001848A (es) Metodo de tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de celulas t